Mission3 and RealityCorp Announce Strategic Alliance
Phoenix, AZ-March 4, 2009-Mission3, Inc., a leading provider of program delivery for the Life Sciences industry, announced today that it has entered into a strategic partnership with Re@lityCorp in order to provide cutting edge technology to emerging Life Science companies. With Re@lityCorp’s unparalleled QA and Testing expertise, along with their trusted practices and standards, and Mission3’s robust suite of
project planning, document management, regulatory submission, and collaborative authoring, the alliance promises to provide efficient, accurate execution of services for client companies in today’s challenging operational environment.
“We are pleased to partner with a company like Re@lityCorp. Given their expertise in the validation and testing arena and their knowledge of technology delivery via SaaS, this partnership can really highlight the value chain for life science companies. With the incredible tightness in the economy and capital markets right now, both Mission3 and Re@lityCorp offer companies mission critical technology without making huge
investments in working capital as well as time and resources.”, said Dirk Karsten Beth, President and Founder of Mission3.
“Our clients are always under significant time and resource constraints to deliver projects on schedule and within budget. They are looking for timely and easily accessible ways to access, maintain, approve, retrieve, and collaborate on project related documentation. Mission3’s web based, project integrated electronic documentation management solution is a home run for our clients and users. We are really looking forward to extend the Mission3 platform and value to our client base”, said Carlton Schowe, President of Re@lityCorp.
About Mission3, Inc.
Mission3 is a leading provider of on-demand program delivery software that merges cutting edge technology with affordability, exclusively for the unique needs of the Life Sciences industry. Mission3 OnDemand is a fully integrated, 21 CFR Part 11 compliant, Document, Project, and Regulatory Submission Management suite that is truly web-based and offered in an collaborative, on-demand (SaaS) environment. Designed for rapid deployment and ease of use, Mission3 OnDemand 3.0 manages all documents within business areas governed by world wide regulatory bodies and corresponding submissions. For more information go to: www.mission3.com
About Re@lity Corp
Re@lityCorp provides state-of-art and industry leading outsourced QA data validation solutions. Our Software as a Service (SaaS) offers our clients unparallel new configuration and amendment deployment speed and leading edge functionality that typically saves our clients up to a 50% reduction in project time and cost without compromising quality. Re@lityCorp’s QA testing platform offers a very compelling value
proposition to our customers. For more information go to: www.realitycorp.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
